CME Group Inc (CME) Shares Sold by Chesley Taft & Associates LLC
Chesley Taft & Associates LLC lessened its holdings in CME Group Inc (NASDAQ:CME) by 10.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,300 shares of the financial services provider’s stock after selling 370 shares during the period. Chesley Taft & Associates LLC’s holdings in CME Group were worth $562,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of CME. Franklin Resources Inc. bought a new position in CME Group during the 1st quarter worth $237,000. BB&T Securities LLC increased its position in CME Group by 41.5% during the 1st quarter. BB&T Securities LLC now owns 6,865 shares of the financial services provider’s stock worth $1,110,000 after buying an additional 2,013 shares during the period. Commonwealth Equity Services LLC increased its position in CME Group by 18.1% during the 1st quarter. Commonwealth Equity Services LLC now owns 28,986 shares of the financial services provider’s stock worth $4,688,000 after buying an additional 4,446 shares during the period. Bayesian Capital Management LP bought a new position in CME Group during the 1st quarter worth $214,000. Finally, The Manufacturers Life Insurance Company increased its position in CME Group by 15.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 423,606 shares of the financial services provider’s stock worth $68,514,000 after buying an additional 56,790 shares during the period. Institutional investors and hedge funds own 84.03% of the company’s stock.
Several research analysts have weighed in on the company. Compass Point assumed coverage on CME Group in a research report on Monday, July 9th. They set a “neutral” rating and a $170.00 price objective on the stock. BidaskClub upgraded CME Group from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Deutsche Bank reiterated a “buy” rating and set a $192.00 price objective (up previously from $185.00) on shares of CME Group in a research report on Thursday. Wells Fargo & Co increased their price objective on CME Group from $170.00 to $175.00 and gave the stock a “market perform” rating in a research report on Monday, July 9th. Finally, Zacks Investment Research upgraded CME Group from a “sell” rating to a “hold” rating in a research report on Wednesday, October 3rd. Five investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $178.93.
CME Group (NASDAQ:CME) last issued its quarterly earnings results on Thursday, July 26th. The financial services provider reported $1.74 EPS for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. CME Group had a return on equity of 9.03% and a net margin of 111.45%. The company had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same quarter last year, the business earned $1.22 earnings per share. CME Group’s revenue was up 14.6% on a year-over-year basis. As a group, equities analysts anticipate that CME Group Inc will post 6.64 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 25th. Investors of record on Monday, September 10th were given a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.59%. The ex-dividend date of this dividend was Friday, September 7th. CME Group’s payout ratio is currently 58.70%.
In related news, President Bryan T. Durkin sold 11,509 shares of the firm’s stock in a transaction dated Monday, August 6th. The stock was sold at an average price of $162.01, for a total value of $1,864,573.09. Following the sale, the president now directly owns 64,862 shares of the company’s stock, valued at $10,508,292.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Martin J. Gepsman sold 300 shares of the firm’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $172.30, for a total value of $51,690.00. Following the completion of the sale, the director now directly owns 42,912 shares in the company, valued at $7,393,737.60. The disclosure for this sale can be found here. Insiders sold 26,688 shares of company stock worth $4,523,957 in the last 90 days. 0.43% of the stock is owned by company insiders.
About CME Group
CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals.
Recommended Story: Analyzing a company’s cash flow statement
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.